uniQure Reports Increased Loss, Pursues UK Regulatory Path for AMT-130 Amidst Clinical Setbacks

summarizeSummary

uniQure reported an increased net loss in Q1 2026 but maintained its cash runway, while pursuing a UK regulatory path for AMT-130 and streamlining operations, despite a clinical setback for AMT-191 and discontinuation of AMT-162.

check_boxKey Events

• Net Loss Widens

  The company reported a net loss of $53.5 million for Q1 2026, an increase from $43.6 million in the same period last year.

• New Regulatory Path for AMT-130

  uniQure plans to submit a UK Marketing Authorization Application for its Huntington's disease gene therapy, AMT-130, in Q3 2026, following positive pre-submission feedback from the MHRA.

• AMT-191 Clinical Dosing Paused

  Additional dosing in the mid- and high-dose cohorts of the Fabry disease program (AMT-191) has been paused due to dose-limiting toxicities (asymptomatic Grade 3 liver enzyme elevations).

• Operational Streamlining

  The company terminated its HEMGENIX supply obligations with CSL Behring and Genezen, which is expected to amortize a $7.3 million intangible asset and release a $5.8 million purchase commitment liability.

auto_awesomeAnalysis

uniQure's Q1 2026 report reveals a widening net loss and a decrease in total cash and investments, signaling ongoing financial challenges. Despite this, the company reaffirmed its cash runway into the second half of 2029. A significant development is the plan to submit a UK Marketing Authorization Application for AMT-130 in Q3 2026, offering a potential regulatory pathway after the FDA's recommendation for a new trial. However, this positive is tempered by a clinical setback in the Fabry disease program (AMT-191), where dosing was paused due to dose-limiting toxicities, and the discontinuation of the ALS program (AMT-162) which was previously announced. The operational streamlining of HEMGENIX manufacturing obligations is a positive step towards reducing future commitments. Investors should monitor the progress of the UK MAA for AMT-130 and the resolution of the AMT-191 clinical hold, as these will be critical for the company's future.